Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
CATB Catabasis Pharmaceuticals, Inc. daily Stock Chart
CATB [NASD]
Catabasis Pharmaceuticals, Inc.
Healthcare | Biotechnology | USA
financial highlights | statements
Index- P/E- EPS (ttm)-80.26 Insider Own2.23% Shs Outstand9.76M Perf Week23.51%
Market Cap64.61M Forward P/E- EPS next Y-3.78 Insider Trans0.00% Shs Float9.44M Perf Month23.97%
Income-25.30M PEG- EPS next Q-0.92 Inst Own31.90% Short Float0.64% Perf Quarter3.76%
Sales0.30M P/S215.37 EPS this Y43.20% Inst Trans- Short Ratio0.78 Perf Half Y-11.92%
Book/sh57.04 P/B0.12 EPS next Y23.00% ROA-76.80% Target Price40.67 Perf Year-56.73%
Cash/sh4.44 P/C1.49 EPS next 5Y- ROE-91.20% 52W Range3.60 - 23.80 Perf YTD51.49%
Dividend- P/FCF- EPS past 5Y-2.20% ROI-189.50% 52W High-73.78% Beta1.59
Dividend %- Quick Ratio10.80 Sales past 5Y- Gross Margin- 52W Low73.33% ATR0.58
Employees38 Current Ratio10.80 Sales Q/Q- Oper. Margin- RSI (14)61.99 Volatility10.70% 13.10%
OptionableNo Debt/Eq0.00 EPS Q/Q74.30% Profit Margin- Rel Volume1.52 Prev Close6.62
ShortableYes LT Debt/Eq0.00 EarningsFeb 12 BMO Payout- Avg Volume77.30K Price6.24
Recom- SMA2024.01% SMA509.32% SMA200-33.27% Volume88,959 Change-5.74%
Oct-05-17Reiterated Oppenheimer Outperform $4 → $7
Feb-02-17Downgrade Citigroup Buy → Neutral
Dec-22-16Initiated H.C. Wainwright Buy $14
Jun-08-16Reiterated Wedbush Outperform $27 → $17
Jul-20-15Initiated Wedbush Outperform $27
Jul-20-15Initiated Oppenheimer Outperform $28
Jul-20-15Initiated Citigroup Buy $21
Jan-15-19 11:10AM  Is Catabasis Pharmaceuticals, Inc.s (NASDAQ:CATB) CEO Overpaid Relative To Its Peers? Simply Wall St.
Jan-14-19 01:42AM  Catabasis Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy? Zacks
Jan-11-19 09:30AM  Is Catabasis Pharmaceuticals (CATB) Outperforming Other Medical Stocks This Year? Zacks
Jan-08-19 08:38AM  Agenus (AGEN) Surges: Stock Moves 9.4% Higher Zacks
Jan-04-19 08:00AM  Catabasis Pharmaceuticals Appoints Gregg Lapointe to its Board of Directors Business Wire +8.04%
Jan-03-19 08:08AM  Catabasis Pharmaceuticals Phase 3 PolarisDMD Clinical Trial for Edasalonexent in Duchenne Muscular Dystrophy Progress Update and Additional Trial Sites Open for Enrollment Business Wire
Dec-31-18 04:31PM  Why Canada Goose Holdings, Catabasis Pharmaceuticals, and Globalstar Jumped Today Motley Fool +7.13%
Dec-24-18 08:00AM  Catabasis Pharmaceuticals Announces Reverse Stock Split Business Wire -7.29%
Dec-18-18 08:12AM  Catella Divests Card Issuing Operations in Luxembourg to Advanzia Bank and Completes Strategic Review PR Newswire
Dec-12-18 02:22AM  Catella and Söderberg & Partners in Strategic Partnership PR Newswire
Nov-28-18 08:55AM  Consolidated Research: 2018 Summary Expectations for MyoKardia, Bristow Group, The Chefs' Warehouse, Catabasis Pharmaceuticals, Casa, and EP Energy Fundamental Analysis, Key Performance Indications GlobeNewswire
Nov-27-18 08:00AM  Catabasis Pharmaceuticals Announces Publication of Phase 1 Clinical Results of Edasalonexent (CAT-1004) in Duchenne Muscular Dystrophy Business Wire
Nov-16-18 05:48PM  Edited Transcript of CATB earnings conference call or presentation 13-Nov-18 1:30pm GMT Thomson Reuters StreetEvents
Nov-15-18 09:26AM  Does The Catabasis Pharmaceuticals Inc (NASDAQ:CATB) Share Price Fall With The Market? Simply Wall St.
Nov-13-18 08:15AM  Catabasis Pharmaceuticals: 3Q Earnings Snapshot Associated Press
08:05AM  Catabasis Pharmaceuticals Reports Third Quarter 2018 Financial Results and Reviews Business Progress Business Wire
07:45AM  Catabasis Pharmaceuticals Announces Collaboration with the University of Texas Southwestern to Explore the Potential Benefits of Edasalonexent on Cardiac Function in Duchenne and Becker Muscular Dystrophies Business Wire
Nov-02-18 08:00AM  Catabasis Pharmaceuticals and Parent Project Muscular Dystrophy to Host a Webinar on PolarisDMD: Phase 3 Clinical Trial of Edasalonexent (CAT-1004) in Duchenne Muscular Dystrophy Business Wire
Oct-30-18 08:00AM  Catabasis Pharmaceuticals to Report Third Quarter 2018 Financial Results and Recent Corporate Developments on Tuesday, November 13 Business Wire
Oct-18-18 08:25AM  Recent Analysis Shows Progenics Pharmaceuticals, Catabasis Pharmaceuticals, Warrior Met Coal, Preformed Line Products, Express, and Sanmina Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire +8.39%
Oct-17-18 02:20PM  Flagship biotech startup leases space from struggling Catabasis American City Business Journals
Oct-04-18 09:20AM  Bet on Rising P/E Investing With These 5 Top-Ranked Stocks Zacks
Oct-03-18 08:00AM  Catabasis Pharmaceuticals Presents Data Supporting MRI T2 as a Potential Marker of Clinical Outcome in Duchenne Muscular Dystrophy at the World Muscle Society Congress Business Wire -8.53%
Sep-25-18 08:00AM  Catabasis Pharmaceuticals Initiates Phase 3 PolarisDMD Clinical Trial for Edasalonexent in Duchenne Muscular Dystrophy Business Wire
Sep-19-18 08:00AM  Catabasis Pharmaceuticals to Present New Edasalonexent Clinical Results and Phase 3 Trial Design in Duchenne Muscular Dystrophy at the World Muscle Society Congress Business Wire +5.77%
Sep-13-18 09:13AM  Spectrum Pharma Includes First-Line NSCLC in Poziotinib Study Zacks
Aug-27-18 07:45AM  Recent Analysis Shows KalVista Pharmaceuticals, IZEA, Sonic Automotive, Catabasis Pharmaceuticals, ANI Pharmaceuticals, and Clovis Oncology Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Aug-09-18 09:48AM  Catabasis Pharmaceuticals: 2Q Earnings Snapshot Associated Press
08:05AM  Catabasis Pharmaceuticals Reports Second Quarter 2018 Financial Results and Reviews Business Progress Business Wire
06:30AM  Catabasis Pharmaceuticals Inc to Host Earnings Call ACCESSWIRE
Aug-08-18 08:00AM  Catabasis Pharmaceuticals to Present at 2018 Wedbush PacGrow Healthcare Conference Business Wire +9.16%
Jul-26-18 08:00AM  Free Technical Insights on BioPharmX and Three Other Biotech Stocks ACCESSWIRE +6.01%
08:00AM  Catabasis Pharmaceuticals to Report Second Quarter 2018 Financial Results and Recent Corporate Developments on Thursday, August 9 Business Wire
Jul-09-18 08:00AM  Catabasis Pharmaceuticals Announces Plans for Edasalonexent Phase 3 POLARIS DMD Trial in Duchenne Muscular Dystrophy Business Wire
Jun-26-18 07:45AM  Analysis: Positioning to Benefit within The Manitowoc, Omeros, Catabasis Pharmaceuticals, Zayo Group, Covanta Holding, and Seattle Genetics Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Jun-25-18 03:40PM  Catabasis Pharmaceuticals Presents New Edasalonexent Clinical Biomarker Data Showing NF-kB Inhibition and Target Engagement in the MoveDMD® Trial Business Wire
08:30AM  Catabasis Pharmaceuticals, Edasalonexent for the Treatment of Duchenne Muscular Dystrophy Showing Early Clinical Success ACCESSWIRE
Jun-22-18 04:05PM  Catabasis Pharmaceuticals Announces Closing of $42M Underwritten Public Offering Business Wire
Jun-20-18 09:10AM  Catabasis Pharmaceuticals Announces Pricing of $42 Million Underwritten Public Offering Business Wire -14.71%
Jun-18-18 08:00AM  Catabasis Pharmaceuticals to Present at Upcoming Scientific and Advocacy Conferences Business Wire -20.90%
Jun-06-18 12:58PM  Catabasis Pharmaceuticals Incs (NASDAQ:CATB) Path To Profitability Simply Wall St.
May-11-18 05:09PM  Keryx (KERX) Loss Narrower than Expected in Q1, Sales Beat Zacks
02:41PM  Edited Transcript of CATB earnings conference call or presentation 10-May-18 12:30pm GMT Thomson Reuters StreetEvents
09:42AM  Intrexon (XON) Q1 Loss Narrower Than Expected, Revenues Miss Zacks
05:59AM  Endocyte (ECYT) Q1 Loss Narrower Than Expected, Shares Up Zacks
May-10-18 12:35PM  Catalyst (CPRX) Posts In-Line Q1 Loss, Pipeline Progresses Zacks -8.94%
09:12AM  Catabasis Pharmaceuticals: 1Q Earnings Snapshot Associated Press
08:05AM  Catabasis Pharmaceuticals Reports First Quarter 2018 Financial Results and Reviews Business Progress Business Wire
May-09-18 10:35AM  Does Catabasis Pharmaceuticals Incs (NASDAQ:CATB) Past Performance Indicate A Stronger Future? Simply Wall St. +7.19%
08:15AM  Market Trends Toward New Normal in Church & Dwight Co., Rent-A-Center, Teradata, Catabasis Pharmaceuticals, Tronox, and Callaway Golf Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
May-04-18 02:17PM  AMAG Pharma (AMAG) Q1 Loss Wider Than Expected, Lifts View Zacks
11:24AM  Sarepta (SRPT) Q1 Loss Narrows, Exondys 51 Sales Impress Zacks
May-03-18 08:00AM  Catabasis Pharmaceuticals to Report First Quarter 2018 Financial Results and Recent Corporate Developments on Thursday, May 10 Business Wire
May-02-18 10:59AM  Novo Nordisk (NVO) Beats Q1 Earnings Estimates, Sales Miss Zacks
10:49AM  Zoetis (ZTS) Beats on Q1 Earnings & Sales, Retains '18 View Zacks
Apr-26-18 10:09AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
08:07AM  Benzinga's Daily Biotech Pulse: Catabasis Soars On Trial Results, Eloxx Listing, Biomarin Earnings Benzinga
Apr-25-18 05:00PM  Catabasis Pharmaceuticals Presents New Edasalonexent Data Showing Significantly Slowed Duchenne Muscular Dystrophy Disease Progression as Measured by MRI Through One Year of Treatment Business Wire
07:59AM  Catabasis Pharmaceuticals, Inc. (CATB) Sees Hammer Chart Pattern: Time to Buy? Zacks
Apr-18-18 08:00AM  Catabasis Pharmaceuticals to Present Results from the MoveDMD® Trial of Edasalonexent in Duchenne Muscular Dystrophy at the American Academy of Neurology 70th Annual Meeting Business Wire
Apr-17-18 06:35PM  Alnylam (ALNY) Reports Positive Data for RNAi Candidate Zacks
06:33PM  Alkermes Rallies as FDA Accepts NDA for Depression Drug Zacks
04:01PM  Catabasis Pharmaceuticals Aligns Resources to Focus on Lead Program Edasalonexent for the Treatment of Duchenne Muscular Dystrophy Business Wire
Apr-13-18 11:13AM  Here's Why Geron Stock Surged More Than 90% in 6 Months Zacks
Apr-12-18 11:37AM  FDA Lifts Clinical Hold on Bellicum's (BLCM) T Cell Therapy Zacks
Apr-11-18 04:11PM  Epizyme (EPZM) Publishes Tazemetostat Phase I Data, Stock Up Zacks
09:36AM  Spectrum Pharma Stock Up on Positive Lung Cancer Study Data Zacks
Mar-23-18 07:00AM  Wired News FDA Permitted a Single Registration Trial Assessing Eiger BioPharmas Lonafarnib in HDV to Support NDA Filing ACCESSWIRE -5.42%
Mar-19-18 12:12PM  Edited Transcript of CATB earnings conference call or presentation 15-Mar-18 8:30pm GMT Thomson Reuters StreetEvents
Mar-15-18 05:39PM  Catabasis Pharmaceuticals posts 4Q loss Associated Press
04:10PM  Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Reviews Business Progress Business Wire
12:15PM  Catabasis Pharmaceuticals Inc to Host Earnings Call ACCESSWIRE
Mar-11-18 01:19PM  Catella Strengthens UK Presence by Signing a Conditioned Share Purchase Agreement to Acquire Majority Stake in APAM Ltd PR Newswire
Mar-08-18 08:00AM  Catabasis Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results and Recent Corporate Developments on Thursday, March 15 Business Wire
Mar-07-18 08:15AM  Detailed Research: Economic Perspectives on RPC, Catabasis Pharmaceuticals, Zayo Group, Catalent, ARRIS International, and McCormick & Company What Drives Growth in Today's Competitive Landscape GlobeNewswire
Mar-02-18 08:30AM  Todays Research Reports on Trending Tickers: Catabasis Pharmaceuticals and Synergy Pharmaceuticals ACCESSWIRE
Feb-14-18 08:30AM  Todays Research Reports on Trending Tickers: Catabasis Pharmaceuticals and ImmunoCellular Therapeutics ACCESSWIRE -10.90%
Feb-13-18 08:00AM  Catabasis Pharmaceuticals Reports Edasalonexent Preserved Muscle Function and Substantially Slowed Duchenne Muscular Dystrophy Disease Progression Through More Than One Year of Treatment Business Wire +24.80%
Jan-09-18 10:42AM  Amgen Announces Acceptance of MAA for Evenity in Europe Zacks
Jan-08-18 05:54PM  Ultragenyx Announces Interim Data from Early Stage Study Zacks
Dec-06-17 02:01AM  Summit, Santhera, Catabasis and Duchenne UK to Host DMD Awareness Day GlobeNewswire
02:00AM  Santhera Pharmaceuticals, Summit Therapeutics, Catabasis Pharmaceuticals and Duchenne UK to host Duchenne Muscular Dystrophy Awareness Day GlobeNewswire
01:01AM  Santhera Pharmaceuticals, Summit Therapeutics, Catabasis Pharmaceuticals and Duchenne UK to host Duchenne Muscular Dystrophy Awareness Day GlobeNewswire
Nov-21-17 08:00AM  Catabasis Pharmaceuticals to Present at 29th Annual Piper Jaffray Healthcare Conference Business Wire
Nov-14-17 04:32PM  Edited Transcript of CATB earnings conference call or presentation 9-Nov-17 9:30pm GMT Thomson Reuters StreetEvents -5.88%
Nov-13-17 08:20AM  Analysis: Positioning to Benefit within Catabasis, Flowserve, MGIC Investment, Arrowhead, Silver Spring, and Live Nation Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire -6.59%
Nov-09-17 04:17PM  Catabasis Pharmaceuticals posts 3Q loss Associated Press
04:10PM  Catabasis Pharmaceuticals Reports Third Quarter 2017 Financial Results and Reviews Business Progress Business Wire
11:55AM  Is Catabasis Pharmaceuticals Inc (CATB) A Financially Sound Company? Simply Wall St.
10:10AM  Catabasis Pharmaceuticals Inc to Host Earnings Call ACCESSWIRE
Nov-02-17 08:00AM  Catabasis Pharmaceuticals to Report Third Quarter 2017 Financial Results and Recent Corporate Developments on Thursday, November 9 Business Wire -6.12%
Oct-26-17 08:00AM  Catabasis Pharmaceuticals Announces Upcoming Presentation on CAT-5571 as a Potential Treatment for Cystic Fibrosis at the 31st Annual North American Cystic Fibrosis Conference Business Wire
Oct-06-17 07:30AM  Corporate News Blog - Catabasis Pharma Shares Positive Results from Phase-2 MoveDMD Trials for Assessing Edasalonexent for Treatment of Duchenne Muscular Dystrophy ACCESSWIRE -12.32%
Oct-05-17 11:47AM  Catabasis' DMD Candidate Slows Disease Progression, Stock Up Zacks -6.27%
08:00AM  Today's Research Reports on Trending Tickers: Catabasis Pharmaceuticals and Momenta Pharmaceuticals ACCESSWIRE
Oct-04-17 12:38PM  Evidence of Biotech Froth Continues to Mount Bloomberg +7.07%
08:30AM  Catabasis Pharmaceuticals (CATB) Surges: Stock Moves 7.2% Higher Zacks
07:44AM  Catabasis's stock rockets after positive trial results of Duchenne muscular dystrophy treatment MarketWatch
04:55AM  Armed with fresh trial data, Catabasis doubles down on Duchenne drug American City Business Journals
04:30AM  Catabasis Pharmaceuticals Reports Positive Results from Open-Label Extension of Phase 2 MoveDMD® Trial Evaluating Edasalonexent in Duchenne Muscular Dystrophy and Plans to Initiate Phase 3 Clinical Trial in First Half 2018 Business Wire
Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics based on safely metabolized and rationally targeted (SMART) linker drug discovery platform in the United States. The company's lead product candidate is Edasalonexent, an oral small molecule, which completed Phase II clinical trial for the treatment of duchenne muscular dystrophy (DMD), as well as Phase I clinical trial for the treatment of additional rare diseases. It is also involved in developing SMART linker conjugates that are in preclinical stage of development, including CAT-5571 for cystic fibrosis (CF) and malfunctioning of CF transmembrane conductance regulator, as well as for the clearance of pathogens, such as P. aeruginosa and B. cenocepacia; and CAT-4001 for the treatment of severe and rare neurodegenerative diseases consisting of Friedreich's ataxia and amyotrophic lateral sclerosis. In addition, the company offers CAT-2000 compounds, which are SMART linker conjugates of nicotinic acid and EPA that are used for the treatment of nonalcoholic steatohepatitis. Catabasis Pharmaceuticals, Inc. has a pre-clinical joint research collaboration agreement with Sarepta Therapeutics, Inc. to explore a combination drug treatment approach for DMD; and collaboration with the University of Texas Southwestern to study the potential benefits of edasalonexent treatment. The company was founded in 2008 and is based in Cambridge, Massachusetts.
open in yahoo | open in reuters | open in google